Q2 2025 Alkermes Plc Earnings Call Transcript
Key Points
- Alkermes PLC (ALKS) reported strong financial performance in Q2 2025, with total revenues of $390.7 million and a 14% year-over-year growth in net sales from proprietary products.
- The company has a robust financial position with no debt and over $1 billion in cash, providing significant strategic optionality.
- Positive top-line results from the Vibrance-1 Phase-2 study of alixorexton in narcolepsy type-1 were announced, showing significant effects on wakefulness and a well-tolerated profile.
- Alkermes PLC (ALKS) is on track to deliver record revenues from its proprietary products in 2025, with expectations to finish the year towards the higher end of its financial guidance.
- The company is advancing its pipeline with two additional orexin candidates, ALKS 4510 and ALK 7290, targeting conditions beyond central disorders of hypersomnias.
- R&D expenses increased to $77.4 million in Q2 2025, reflecting investments in Phase-2 studies, which could impact short-term profitability.
- The company faces challenges in the competitive landscape, particularly in differentiating its orexin two receptor agonist from competitors like Takeda.
- There is a focus on visual adverse events in the orexin program, which could pose regulatory and commercial challenges if not addressed adequately.
- The cataplexy endpoint in the Vibrance-1 study showed variability, with statistical significance achieved only at one dose, indicating potential challenges in achieving consistent results.
- Alkermes PLC (ALKS) needs to confirm its Phase-3 dosing strategy, which depends on further analysis and results from ongoing studies, potentially delaying regulatory submissions.
Greetings, and welcome to the Alkermes second quarter 2025 financial results conference call. My name is Rob, and I'll be your operator for today's call. (Operator Instructions). Please note that this conference is being recorded.
I'll now turn the call over to Sandra Coombs, Senior Vice President of Investor Relations and Corporate Affairs. Sandy, you may now begin.
Good morning. Welcome to the Alkermes plc conference call to discuss our financial results and business update for the quarter ended June 30, 2025. With me today are Richard Pops, our CEO; and Blair Jackson, our Chief Operating Officer; Todd Nichols, our Chief Commercial Officer; Dr. Craig Hopkinson, our Chief Medical Officer; and [Dr. Markus Jans, Vice President of Clinical Development].
A slide presentation along with our press release, related financial tables and reconciliations of the GAAP to non-GAAP financial measures that we'll discuss today are available on the Investors section
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
